PMCC Resources

Here are the staff publications for June 2017.

Compiled by the Health Sciences Library (RMH, RWH, PMCC and Victorian Mental Health) 3rd July 2017.

  1. Amarasena I, Herschtal A, D'Costa I, Fua T, Tiong A, Geddes V, Tran P, Liu C, Corry J. Outcomes of Routine Intensity Modulated Radiation Therapy Quality Assurance in a Large Head and Neck Cancer Center. International Journal of Radiation Oncology Biology Physics 2017;98:541-6.
  2. Anderson MA, Tam C, Lew TE, Juneja S, Juneja M, Westerman D, Wall M, Lade S, Gorelik A, Huang DCS, Seymour JF, Roberts AW. Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax. Blood 2017;129:3362-70.
  3. Antony R, Herschtal A, Todd S, Phillips C, Haworth A. A pilot study on geometrical uncertainties for intra ocular cancers in radiotherapy. Australasian Physical & Engineering Sciences in Medicine 2017;40:433-9.
  4. Beatty L, Kemp E, Binnion C, Turner J, Milne D, Butow P, Lambert S, Yates P, Yip D, Koczwara B. Uptake and adherence to an online intervention for cancer-related distress: older age is not a barrier to adherence but may be a barrier to uptake. Supportive Care in Cancer 2017;25:1905-14.
  5. Bonaventura A, O'Connell RL, Mapagu C, Beale PJ, McNally OM, Mileshkin LR, Grant PT, Hadley AM, Goh JCH, Sjoquist KM, Martyn J, DeFazio A, Scurry J, Friedlander ML, Paragon I. Paragon (ANZGOG-0903): Phase 2 Study of Anastrozole in Women With Estrogen or Progesterone Receptor-Positive Platinum-Resistant or -Refractory Recurrent Ovarian Cancer. International Journal of Gynecological Cancer 2017;27:900-6.
  6. Byrne DJ, Deb S, Takano EA, Fox SB. GATA3 expression in triple-negative breast cancers. Histopathology 2017;71:63-71.
  7. Chang JH, Gandhidasan S, Finnigan R, Whalley D, Nair R, Herschtal A, Eade T, Kneebone A, Ruben J, Foote M, Siva S. Stereotactic Ablative Body Radiotherapy for the Treatment of Spinal Oligometastases. Clinical Oncology (R Coll Radiol) 2017;29:e119-e25.
  8. Chittleborough TJ, Warrier SK, Heriot AG, Kalady M, Church J. Dispelling misconceptions in the management of familial adenomatous polyposis. ANZ Journal of Surgery 2017;87:441-5.
  9. Christidis D, McGrath S, Perera M, Manning T, Bolton D, Lawrentschuk N. Minimally invasive surgical therapies for benign prostatic hypertrophy: The rise in minimally invasive surgical therapies. Prostate International 2017;5:41-6.
  10. Chrysanthou E, Gorringe KL, Joseph C, Craze M, Nolan CC, Diez-Rodriguez M, Green AR, Rakha EA, Ellis IO, Mukherjee A. Phenotypic characterisation of breast cancer: the role of CDC42. Breast Cancer Research and Treatment 2017;164:317-25.
  11. Corona SP, Sobhani N, Ianza A, Roviello G, Mustacchi G, Bortul M, Zanconati F, Generali D. Erratum to: Advances in systemic therapy for metastatic breast cancer: future perspectives. Medical Oncology 2017;34:130.
  12. Corry J, Bressel M, Fua T, Herschtal A, Solomon B, Porceddu SV, Wratten C, Rischin D. Prospective Study of Cetuximab, Carboplatin, and Radiation Therapy for Patients With Locally Advanced Head and Neck Squamous Cell Cancer Unfit for Cisplatin. International Journal of Radiation Oncology Biology Physics 2017;98:948-54.
  13. de la Cruz-Merino L, Di Guardo L, Grob JJ, Venosa A, Larkin J, McArthur GA, Ribas A, Ascierto PA, Evans JTR, Gomez-Escobar A, Barteselli G, Eng S, Hsu JJ, Uyei A, Dreno B. Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study. Journal of Translational Medicine 2017;15:146.
  14. Dendle C, Gilbertson M, Spelman T, Stuart RL, Korman TM, Thursky K, Opat S, McQuilten Z. Infection is an Independent Predictor of Death in Diffuse Large B Cell Lymphoma. Scientific Reports 2017;7:4395.
  15. Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, Jahkola T, Bowles TL, Testori A, Beitsch PD, Hoekstra HJ, Moncrieff M, Ingvar C, Wouters M, Sabel MS, Levine EA, Agnese D, Henderson M, Dummer R, Rossi CR, Neves RI, Trocha SD, Wright F, Byrd DR, Matter M, Hsueh E, MacKenzie-Ross A, Johnson DB, Terheyden P, Berger AC, Huston TL, Wayne JD, Smithers BM, Neuman HB, Schneebaum S, Gershenwald JE, Ariyan CE, Desai DC, Jacobs L, McMasters KM, Gesierich A, Hersey P, Bines SD, Kane JM, Barth RJ, McKinnon G, Farma JM, Schultz E, Vidal-Sicart S, Hoefer RA, Lewis JM, Scheri R, Kelley MC, Nieweg OE, Noyes RD, Hoon DSB, Wang HJ, Elashoff DA, Elashoff RM. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. New England Journal of Medicine 2017;376:2211-22.
  16. Flynn A, Dwight T, Benn D, Deb S, Colebatch AJ, Fox S, Harris J, Duncan EL, Robinson B, Hogg A, Ellul J, To H, Duong C, Miller JA, Yates C, James P, Trainer A, Gill AJ, Clifton-Bligh R, Hicks RJ, Tothill RW. Cousins not twins: intratumoural and intertumoural heterogeneity in syndromic neuroendocrine tumours. Journal of Pathology 2017;242:273-83.
  17. Geurts N, Lamb AD, Lawrentschuk N, Murphy DG. Prostate-specific membrane antigen radioguided surgery: a promising utility. BJU International 2017;120:5-6.
  18. Hatt M, Lee JA, Schmidtlein CR, Naqa IE, Caldwell C, De Bernardi E, Lu W, Das S, Geets X, Gregoire V, Jeraj R, MacManus MP, Mawlawi OR, Nestle U, Pugachev AB, Schoder H, Shepherd T, Spezi E, Visvikis D, Zaidi H, Kirov AS. Classification and evaluation strategies of auto-segmentation approaches for PET: Report of AAPM task group No. 211. Medical Physics 2017;44:e1-e42.
  19. Kapoor J, Lamb AD, Murphy DG. Re: Diagnostic Accuracy of Multi-parametric MRI and TRUS Biopsy in Prostate Cancer (PROMIS): A Paired Validating Confirmatory Study. European Urology 2017;72:151.
  20. Kats LM, Vervoort SJ, Cole R, Rogers AJ, Gregory GP, Vidacs E, Li J, Nagaraja R, Yen KE, Johnstone RW. A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML. Leukemia 2017;31:1466-70.
  21. Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, Jervis S, van Leeuwen FE, Milne RL, Andrieu N, Goldgar DE, Terry MB, Rookus MA, Easton DF, Antoniou AC, and the B, Consortium BC, McGuffog L, Evans DG, Barrowdale D, Frost D, Adlard J, Ong KR, Izatt L, Tischkowitz M, Eeles R, Davidson R, Hodgson S, Ellis S, Nogues C, Lasset C, Stoppa-Lyonnet D, Fricker JP, Faivre L, Berthet P, Hooning MJ, van der Kolk LE, Kets CM, Adank MA, John EM, Chung WK, Andrulis IL, Southey M, Daly MB, Buys SS, Osorio A, Engel C, Kast K, Schmutzler RK, Caldes T, Jakubowska A, Simard J, Friedlander ML, McLachlan SA, Machackova E, Foretova L, Tan YY, Singer CF, Olah E, Gerdes AM, Arver B, Olsson H. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA 2017;317:2402-16.
  22. Lasocki A, Gaillard F, Harrison SJ. Multiple myeloma of the spine. Neuroradiology Journal 2017;30:259-68.
  23. Lehrnbecher T, Robinson P, Fisher B, Alexander S, Ammann RA, Beauchemin M, Carlesse F, Groll AH, Haeusler GM, Santolaya M, Steinbach WJ, Castagnola E, Davis BL, Dupuis LL, Gaur AH, Tissing WJE, Zaoutis T, Phillips R, Sung L. Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update. Journal of Clinical Oncology 2017;35:2082-94.
    Leong T, Smithers BM, Haustermans K, Michael M, Gebski V, Miller D, Zalcberg J, Boussioutas A, Findlay M, O'Connell RL, Verghis J, Willis D, Kron T, Crain M, Murray WK, Lordick F, Swallow C, Darling G, Simes J, Wong R. TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG. Annals of Surgical Oncology 2017;24:2252-8.
  24. Mansour M, Teo ZL, Luen SJ, Loi S. Advancing Immunotherapy in Metastatic Breast Cancer. Current Treatment Options in Oncology 2017;18:35.
  25. McBride KA, Ballinger ML, Schlub TE, Young MA, Tattersall MHN, Kirk J, Eeles R, Killick E, Walker LG, Shanley S, Thomas DM, Mitchell G. Psychosocial morbidity in TP53 mutation carriers: is whole-body cancer screening beneficial? Familial Cancer 2017;16:423-32.
  26. Murphy DG, Sweeney CJ, Tombal B. "Gotta Catch 'em All", or Do We? Pokemet Approach to Metastatic Prostate Cancer. European Urology 2017;72:1-3.
  27. Nolan E, Savas P, Policheni AN, Darcy PK, Vaillant F, Mintoff CP, Dushyanthen S, Mansour M, Pang JB, Fox SB, Kathleen Cuningham Foundation Consortium for Research into Familial Breast C, Perou CM, Visvader JE, Gray DHD, Loi S, Lindeman GJ. Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer. Science Translational Medicine 2017;9.
  28. Pang JB, Savas P, Fellowes AP, Mir Arnau G, Kader T, Vedururu R, Hewitt C, Takano EA, Byrne DJ, Choong DY, Millar EK, Lee CS, O'Toole SA, Lakhani SR, Cummings MC, Mann GB, Campbell IG, Dobrovic A, Loi S, Gorringe KL, Fox SB. Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer. Modern Pathology 2017;30:952-63.
  29. Parakh S, Park JJ, Mendis S, Rai R, Xu W, Lo S, Drummond M, Rowe C, Wong A, McArthur G, Haydon A, Andrews MC, Cebon J, Guminski A, Kefford RF, Long GV, Menzies AM, Klein O, Carlino MS. Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. British Journal of Cancer 2017;116:1558-63.
  30. Phillips C, Jeffree R, Khasraw M. Reply to Dr Altundag from the authors of 'Management of breast cancer brain metastases; a practical review'. Breast 2017;34:133.
  31. Poder J, Smith RL, Shelton N, Whitaker M, Butler D, Haworth A. High dose rate brachytherapy source measurement intercomparison. Australasian Physical & Engineering Sciences in Medicine 2017;40:377-83.
  32. Pomery A, Schofield P, Xhilaga M, Gough K. Pragmatic, consensus-based minimum standards and structured interview to guide the selection and development of cancer support group leaders: a protocol paper. BMJ Open 2017;7:e014408.
  33. Saya S, Killick E, Thomas S, Taylor N, Bancroft EK, Rothwell J, Benafif S, Dias A, Mikropoulos C, Pope J, Chamberlain A, Gunapala R, Committee SSS, Izatt L, Side L, Walker L, Tomkins S, Cook J, Barwell J, Wiles V, Limb L, Eccles D, Leach MO, Shanley S, Gilbert FJ, Hanson H, Gallagher D, Rajashanker B, Whitehouse RW, Koh DM, Sohaib SA, Evans DG, Eeles RA. Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls. Familial Cancer 2017;16:433-40.
  34. Shaw T, Yates P, Moore B, Ash K, Nolte L, Krishnasamy M, Nicholson J, Rynderman M, Avery J, Jefford M. Development and evaluation of an online educational resource about cancer survivorship for cancer nurses: a mixed-methods sequential study. European Journal of Cancer Care (Engl) 2017;26.
  35. Shustov A, Coiffier B, Horwitz S, Sokol L, Pro B, Wolfson J, Balser B, Eisch R, Popplewell L, Prince HM, Allen SL, Piekarz R, Bates S. Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials. Leukemia & Lymphoma 2017;58:2335-41.
  36. Siva S. Prostate-Specific Membrane Antigen PET Before Aggressive Local Therapy to the Sternum. International Journal of Radiation Oncology Biology Physics 2017;98:494-5.
    Siva S, Callahan J, Pryor D, Martin J, Lawrentschuk N, Hofman MS. Utility of 68 Ga prostate specific membrane antigen - positron emission tomography in diagnosis and response assessment of recurrent renal cell carcinoma. Journal of Medical Imaging and Radiation Oncology 2017;61:372-8.
  37. Siva S, Slotman BJ. Stereotactic Ablative Body Radiotherapy for Lung Metastases: Where is the Evidence and What are We Doing With It? Seminars in Radiation Oncology 2017;27:229-39.
  38. Small W, Jr., Bacon MA, Bajaj A, Chuang LT, Fisher BJ, Harkenrider MM, Jhingran A, Kitchener HC, Mileshkin LR, Viswanathan AN, Gaffney DK. Cervical cancer: A global health crisis. Cancer 2017;123:2404-12.
  39. Trigos AS, Pearson RB, Papenfuss AT, Goode DL. Altered interactions between unicellular and multicellular genes drive hallmarks of transformation in a diverse range of solid tumors. Proceedings of the National Academy of Sciences U S A 2017;114:6406-11.
  40. Trubiano JA, Dickinson M, Thursky KA, Spelman T, Seymour JF, Slavin MA, Worth LJ. Incidence, etiology and timing of infections following azacitidine therapy for myelodysplastic syndromes. Leukemia & Lymphoma 2017;58:2379-86.
  41. Tyler DS, Vappiani J, Caneque T, Lam EYN, Ward A, Gilan O, Chan YC, Hienzsch A, Rutkowska A, Werner T, Wagner AJ, Lugo D, Gregory R, Ramirez Molina C, Garton N, Wellaway CR, Jackson S, MacPherson L, Figueiredo M, Stolzenburg S, Bell CC, House C, Dawson SJ, Hawkins ED, Drewes G, Prinjha RK, Rodriguez R, Grandi P, Dawson MA. Click chemistry enables preclinical evaluation of targeted epigenetic therapies. Science 2017;356:1397-401.
  42. van den Bergh RC, Zargar H, Heijmink S, Bozin M, Murphy DG, van der Poel HG. Reducing the rate of biopsy Gleason undergrading may not improve biochemical recurrence rates in active surveillance candidates. Minerva Urologica e Nefrologica 2017;69:359-65.
  43. Youssef M, Cuddihy A, Darido C. Long-Lived Epidermal Cancer-Initiating Cells. Int J Mol Sci 2017;18.
  44. Zhao J, van Mierlo KMC, Gomez-Ramirez J, Kim H, Pilgrim CHC, Pessaux P, Rensen SS, van der Stok EP, Schaap FG, Soubrane O, Takamoto T, Vigano L, Winkens B, Dejong CHC, Olde Damink SWM, Chemotherapy-Associated Liver Injury c. Systematic review of the influence of chemotherapy-associated liver injury on outcome after partial hepatectomy for colorectal liver metastases. British Journal of Surgery 2017;104:990-1002.

Health Sciences Library [MAP]

PO Royal Melbourne Hospital

PARKVILLE, VIC 3050, AUSTRALIA

Phone: (03) 9342 8617; Fax: (03) 9342 8615

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Learning Resource Centre [MAP]

Level 7A, Peter MacCallum Cancer Centre

305 Grattan Street

MELBOURNE, VIC 3000, AUSTRALIA

Phone: (03) 8559 7194

 

Library Manager

Susan Monaghan;

Phone: (03) 9342 7346

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Health Sciences Library (RMH Building)

Hours (February - November):

Monday - Thursday: 8.30am - 6pm

Friday: 8.30am - 5pm

Summer Hours (December - January):

Monday - Friday: 8:30am - 5pm 


Learning Resource Centre (Peter MacCallum Building)

Staffed Hours (January - December):

Monday - Thursday: 10am - 2pm